



## Klinik für Urologie: Erfasste Publikationen aus 2022

ID: 504244

Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins.

**Abdom Radiol (NY)** 2022; 47(7): 2486-2493; Impact Factor=2.4; Impact Factor 2024=2.2; Typ=Journal Article;

Quentin M, Schimmöller L, Ullrich T, Valentin B, Demetrescu D, **Al-Monajjed R**, **Mally D**, Esposito I, **Albers P**, Antoch G, **Arsov C**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 505885

Kommentar zu „177Lu-PSMA-617 beim metastasierten, kastrationsresistenten Prostatakarzinom“.

**Aktuelle Urol** 2022; 53(2): 106-110; Impact Factor=0.3; Impact Factor 2024=0.4; Typ=Journal Article;Comment;

**Radtke JP**, **Albers P**, Giesel FL

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 501769

Main Focus on Bladder Cancer

**Aktuelle Urol** 2022; 53(02): 135-136; Impact Factor=0.3; Impact Factor 2024=0.4; Typ=

**Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 514455

Nerve-sparing retroperitoneal lymphadenectomy (RLA)

**Aktuelle Urol** 2022; 53(06): 567-577; Impact Factor=0.3; Impact Factor 2024=0.4; Typ=

**Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 501768

[Does robotic radical cystectomy affect oncological outcomes in bladder cancer patients?]

**Aktuelle Urol** 2022; 53(2): 153-158; Impact Factor=0.3; Impact Factor 2024=0.4; Typ=Journal Article;Review;

**Mally D**, Pfister D, Heidenreich A, **Albers P**, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 484953

Nomograms including the UBC® Rapid test to detect primary bladder cancer based on a multicentre dataset.

**BJU Int** 2022; 130(6): 754-763; Impact Factor=4.5; Impact Factor 2024=4.5; Typ=Journal Article;

Meisl CJ, Karakiewicz PI, Einarsson R, Koch S, Hallmann S, Weiß S, Hemdan T, Malmström PU, Styrke J, Sherif A, Hasan MN, Pichler R, Tulchiner G, Palou J, Rodríguez Faba Ó, Hennenlotter J, Stenzl A, Ritter R, **Niegisch G**, **Grunewald CM**, Schlomm T, Friedersdorff F, Barski D, Otto T, Gössl A, Arndt C, Esuvaranathan K, Kesavan NR, Zhijiang Z, Kramer MW, Hennig MJP, Ecke TH

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 506309

Harmonized procedure coding system for surgical procedures and analysis of surgical site infections

(SSI) of five European countries.

**BMC Med Res Methodol** 2022; 22(1): ; Impact Factor=4.0; Impact Factor 2024=3.4; Typ=Clinical Study; Journal Article;

Mellinghoff SC, Bruns C, **Al-Monajjed R**, Cornely FB, Grosheva M, Hampl JA, Jakob C, Koehler FC, Lechmann M, Maged B, Otto-Lambertz C, Rongisch R, Rutz J, Salmanton-Garcia J, Schlachtenberger G, Stemler J, Vehreschild J, Wülfing S, Cornely OA, Liss BJ  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507230

Differential DNA Methylation of THOR and hTAPAS in the Regulation of hTERT and the Diagnosis of Cancer.

**Cancers (Basel)** 2022; 14(18): ; Impact Factor=5.2; Impact Factor 2024=4.4; Typ=Journal Article; Ott P, Araúzo-Bravo MJ, **Hoffmann MJ**, Poyet C, Bendhack ML, Santourlidis S, Erichsen L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 496539

Impact of Surgeon's Experience in Rigid versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores.

**Cancers (Basel)** 2022; 14(4): ; Impact Factor=5.2; Impact Factor 2024=4.4; Typ=Journal Article; Görtz M, Nyarangi-Dix JN, Pursche L, Schütz V, Reimold P, Schwab C, Stenzinger A, Sültmann H, Duensing S, Schlemmer HP, Bonekamp D, Hohenfellner M, **Radtke JP**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 477884

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.

**Clin Epigenetics** 2022; 14(1): ; Impact Factor=5.7; Impact Factor 2024=4.4; Typ=Journal Article; Research Support, Non-U.S. Gov't;

**Müller MR**, **Burmeister A**, **Skowron MA**, **Stephan A**, Bremmer F, **Wakileh GA**, Petzsch P, Köhrer K, **Albers P**, **Nettersheim D**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 511199

Data on the detection of clinically significant prostate cancer by magnetic resonance imaging (MRI)-guided targeted and systematic biopsy.

**Data Brief** 2022; 45(): ; Impact Factor=1.2; Impact Factor 2024=1.4; Typ=Journal Article; Klingebiel M, **Arsov C**, Ullrich T, Quentin M, **Al-Monajjed R**, **Mally D**, Sawicki LM, **Hiester A**, Esposito I, **Albers P**, Antoch G, Schimmöller L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 504754

Arterial input function for quantitative dynamic contrast-enhanced MRI to diagnose prostate cancer.

**Diagn Interv Radiol** 2022; 28(2): 108-114; Impact Factor=2.1; Impact Factor 2024=1.7; Typ=Journal Article;

Ziayee F, Mueller-Lutz A, Gross J, Ullrich T, Quentin M, **Arsov C**, Antoch G, Wittsack HJ, Schimmöller L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 505904

Influence of a Deep Learning Noise Reduction on the CT Values, Image Noise and Characterization of Kidney and Ureter Stones.

**Diagnostics (Basel)** 2022; 12(7): ; Impact Factor=3.6; Impact Factor 2024=3.3; Typ=Journal Article;

Steuwe A, Valentin B, Bethge OT, Ljimani A, **Niegisch G**, Antoch G, Aissa J  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 498951

Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body 68 Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?

**EJNMMI Res** 2022; 12(1): ; Impact Factor=3.2; Impact Factor 2024=3.0; Typ=Journal Article;  
Morawitz J, Kirchner J, Hertelendy J, Loberg C, Schimmöller L, Dabir M, Häberle L, Mamlins E, Antke C,  
**Arsov C**, Antoch G, Sawicki LM  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 488723

Comparison of 3 T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer.

**Eur J Radiol** 2022; 147(): ; Impact Factor=3.3; Impact Factor 2024=3.3; Typ=Journal Article;  
Valentin B, **Arsov C**, Ullrich T, Demetrescu D, Morawitz J, **Al-Monajjed R**, Quentin M, Kirchner J,  
Esposito I, **Albers P**, Antoch G, Schimmöller L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507752

Impact of dynamic contrast-enhanced MRI in 1.5 T versus 3 T MRI for clinically significant prostate cancer detection.

**Eur J Radiol** 2022; 156(): ; Impact Factor=3.3; Impact Factor 2024=3.3; Typ=Journal Article;  
Ziayee F, Schimmöller L, Blondin D, Boschheidgen M, Wilms LM, Vach M, **Arsov C**, **Albers P**, Antoch G,  
Ullrich T  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 472601

MRI grading for the prediction of prostate cancer aggressiveness.

**Eur Radiol** 2022; 32(4): 2351-2359; Impact Factor=5.9; Impact Factor 2024=4.7; Typ=Journal Article;  
Boschheidgen M, Schimmöller L, **Arsov C**, Ziayee F, Morawitz J, Valentin B, Radke KL, **Giessing M**,  
Esposito I, **Albers P**, Antoch G, Ullrich T  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 524595

The SEMITEP Trial: Less May Be More.

**Eur Urol** 2022; 82(2): 180-181; Impact Factor=23.4; Impact Factor 2024=25.2; Typ=Editorial;  
**Albers P**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 531520

Robotic-assisted Versus Laparoscopic Radical Prostatectomy: 12-month Outcomes of the Multicentre Randomised Controlled LAP-01 Trial.

**Eur Urol Focus** 2022; 8(6): 1583-1590; Impact Factor=5.4; Impact Factor 2024=5.6; Typ=Randomized  
Controlled Trial;Multicenter Study;Journal Article;Research Support, Non-U.S. Gov't;  
Stolzenburg JU, Holze S, Arthanareeswaran VK, Neuhaus P, Do HM, Haney CM, Dietel A, Truss MC,  
Stützel KD, Teber D, Hohenfellner M, **Rabenalt R**, **Albers P**, Mende M  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507624

Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and

IMvigor011.

**Eur Urol Focus** 2022; 8(3): 646-647; Impact Factor=5.4; Impact Factor 2024=5.6; Typ=Journal Article;

**Grunewald CM, Niegisch G, Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 466190

Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.

**Eur Urol Oncol** 2022; 5(3): 285-295; Impact Factor=8.2; Impact Factor 2024=9.3; Typ=Journal Article;

Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, **Hiester A, Nini A, Albers P**, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507650

Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review.

**Eur. Urol. Open Sci.** 2022; 44(): 142-149; Impact Factor=2.5; Impact Factor 2024=4.5; Typ=Journal Article;Review;

Kaufmann E, Antonelli L, **Albers P**, Cary C, Gillessen Sommer S, Heidenreich A, Oing C, Oldenburg J, Pierorazio PM, Stephenson AJ, Fankhauser CD

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 505404

Comparative Analysis of Elderly Patients Undergoing Radical Cystectomy With Ureterocutaneostomy or Ileal Conduit With a Special Focus on Bowl Complications Requiring Surgical Revision.

**Front Surg** 2022; 9(): ; Impact Factor=1.8; Impact Factor 2024=1.8; Typ=Journal Article;

**Mally D**, John P, Pfister D, Heidenreich A, **Albers P, Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507916

[Analysis of Efficiency, Cost Structure and Revenues of ALT Free Flaps in Extremity Reconstruction].

**Handchir Mikrochir Plast Chir** 2022; 54(6): 475-483; Impact Factor=0.6; Impact Factor 2024=0.6;

Typ=English Abstract;Journal Article;

Behr B, Schlüchtermann J, **Radtke JP**, Rhombert I, Hellmich S, Sogorski A, Wagner JM, Auhuber T, Lehnhardt M, Wallner C

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 470656

Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach.

**Histopathology** 2022; 80(2): 381-396; Impact Factor=6.4; Impact Factor 2024=4.1; Typ=Journal Article;

Fichtner A, Richter A, Filmar S, Kircher S, Rosenwald A, Küffer S, **Nettersheim D**, Oing C, Marx A, Ströbel P, Bremmer F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 470151

A quantitative polymerase chain reaction based method for molecular subtype classification of urinary bladder cancer-Stromal gene expressions show higher prognostic values than intrinsic tumor genes.

**Int J Cancer** 2022; 150(5): 856-867; Impact Factor=6.4; Impact Factor 2024=4.7; Typ=Journal Article;Research Support, Non-U.S. Gov't;

Olah C, Hahnen C, Nagy N, Musial J, Varadi M, Nyiro G, Györfy B, Hadaschik B, Rawitzer J, Ting S,

Sjödahl G, **Hoffmann MJ**, Reis H, Szarvas T  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 495665

A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial.

**Int J Cancer** 2022; 150(11): 1861-1869; Impact Factor=6.4; Impact Factor 2024=4.7; Typ=Journal Article;

**Arsov C**, **Albers P**, Herkommer K, Gschwend J, Imkamp F, Peters I, Kuczyk M, Hadaschik B, Kristiansen G, Schimmöller L, Antoch G, Rummeny E, Wacker F, Schlemmer H, Benner A, Siener R, Kaaks R, Becker N

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 507736

Palliative Care e-Learning for Physicians Caring for Critically Ill and Dying Patients during the COVID-19 Pandemic: An Outcome Evaluation with Self-Assessed Knowledge and Attitude.

**Int J Environ Res Public Health** 2022; 19(19): ; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Journal Article;

Schwartz J, Schallenburger M, Tenge T, Batzler YN, Schlieper D, Kindgen-Milles D, Meier S, **Niegisch G**, Karger A, Roderburg C, Neukirchen M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 495234

Epigenetics in the Diagnosis and Therapy of Malignant Melanoma.

**Int J Mol Sci** 2022; 23(3): ; Impact Factor=5.6; Impact Factor 2024=4.9; Typ=Journal Article;Review; Santourlidis S, **Schulz WA**, Araúzo-Bravo MJ, Gerovska D, Ott P, Bendhack ML, Hassan M, Erichsen L  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 484952

Value of T2 Mapping MRI for Prostate Cancer Detection and Classification.

**J Magn Reson Imaging** 2022; 56(2): 413-422; Impact Factor=4.4; Impact Factor 2024=3.5; Typ=Journal Article;

Klingebiel M, Schimmöller L, Weiland E, Franiel T, Jannusch K, Kirchner J, Hilbert T, Strecker R, **Arsov C**, Wittsack HJ, **Albers P**, Antoch G, Ullrich T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 514421

Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light ( $\lambda = 453 \pm 10$  nm).

**J Photochem Photobiol B** 2022; 236(): ; Impact Factor=5.4; Impact Factor 2024=3.7; Typ=Journal Article;

Hegmann L, Sturm S, **Niegisch G**, Windolf J, Suschek CV

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 495236

Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.

**J Urol** 2022; 207(3): 617-626; Impact Factor=6.6; Impact Factor 2024=7.5; Typ=Journal Article;

**Che Y**, **Buddensieck C**, **Albers P**, **Lusch A**, **Winter C**, **Siemer RG**, **Hiester A**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 475810

Re: Robotic-Assisted versus Laparoscopic Surgery: Outcomes from the First Multicentre, Randomised,

Patient-Blinded Controlled Trial in Radical Prostatectomy (LAP-01)

**J Urol** 2022; 207(1): 210-210; Impact Factor=6.6; Impact Factor 2024=7.5; Typ=Editorial Material; Stolzenburg JU, Holze S, Neuhaus P, Kyriazis I, Do HM, Dietel A, Truss MC, Grzella CI, Teber D, Hohenfellner M, Rabenalt R, **Albers P**, Mende M  
Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 512725

Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.

**Lancet Oncol** 2022; 23(11): 1441-1450; Impact Factor=51.1; Impact Factor 2024=35.9; Typ=Clinical Trial, Phase II;Multicenter Study;Journal Article;Research Support, Non-U.S. Gov't; Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, **Lorch A**, Aebersold DM, Putora PM, Berthold DR, Zihler D, Zengerling F, Dieing A, Mueller AC, Schaer C, Biaggi C, Gillessen S, Cathomas R  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 509048

Establishment and Evaluation of Dual HDAC/BET Inhibitors as Therapeutic Options for Germ Cell Tumors and Other Urological Malignancies.

**Mol Cancer Ther** 2022; 21(11): 1674-1688; Impact Factor=5.7; Impact Factor 2024=5.5; Typ=Journal Article;  
**Burmeister A**, **Stephan A**, Alves Avelar LA, **Müller MR**, Seiwert A, Höfmann S, Fischer F, Torres-Gomez H, **Hoffmann MJ**, **Niegisch G**, Bremmer F, Petzsch P, Köhrer K, **Albers P**, Kurz T, **Skowron MA**, **Nettersheim D**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 501755

Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer.

**Mol Imaging Biol** 2022; 24(4): 651-658; Impact Factor=3.1; Impact Factor 2024=2.5; Typ=Journal Article;  
Novruzov E, Dendl K, Ndlovu H, Choyke PL, Dabir M, Beu M, Novruzov F, Mehdi E, Guliyev F, Koerber SA, Lawal I, **Niegisch G**, Debus J, Haberkorn U, Sathekge M, Giesel FL  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 505880

Profiling the 3D interaction between germ cell tumors and microenvironmental cells at the transcriptome and secretome level.

**Mol Oncol** 2022; 16(17): 3107-3127; Impact Factor=6.6; Impact Factor 2024=4.5; Typ=Journal Article;  
**Skowron MA**, **Eul K**, **Stephan A**, **Ludwig GF**, **Wakileh GA**, Bister A, **Söhngen C**, Raba K, Petzsch P, Poschmann G, Kuffour EO, Degrandi D, Ali S, Wiek C, Hanenberg H, Münk C, Stühler K, Köhrer K, Mass E, **Nettersheim D**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 468363

The signal transducer CD24 suppresses the germ cell program and promotes an ectodermal rather than mesodermal cell fate in embryonal carcinomas.

**Mol Oncol** 2022; 16(4): 982-1008; Impact Factor=6.6; Impact Factor 2024=4.5; Typ=Journal Article;  
**Skowron MA**, **Becker TK**, **Kurz L**, Jostes S, Bremmer F, Fronhoffs F, Funke K, **Wakileh GA**, **Müller MR**, **Burmeister A**, Lenz T, Stefanski A, Stühler K, Petzsch P, Köhrer K, Altevogt P, **Albers P**, Kristiansen G, Schorle H, **Nettersheim D**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 505982

First-line treatment of metastatic urothelial carcinoma: an update

**Onkologie (Heidelberg, Germany)** 2022; 28(9): 792-798; Impact Factor=0.3; Impact Factor 2024=0.2; Typ=Article;

von Amsberg G, Retz M, De Santis M, **Niegisch G**, Interdisziplinäre Arbeitsgrp Harnb Deutsch Krebsgesell DKG

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 496511

New data on the treatment of patients in uro-oncology Uro-oncology update 2022

**Onkologie (Heidelberg, Germany)** 2022; (); ; Impact Factor=0.3; Impact Factor 2024=0.2; Typ=Article; Grunewald C, Che Y, Lakes J, Rehlinghaus M, **Albers P**, **Niegisch G**

Medline-ID **fehlt**, Web of Science-ID (ISI-LOC) vorhanden

ID: 504920

Engineering a single-chain variable fragment of cetuximab for CAR T-cell therapy against head and neck squamous cell carcinomas.

**Oral Oncol** 2022; 129(): ; Impact Factor=4.8; Impact Factor 2024=3.9; Typ=Journal Article;

Haist C, Poschinski Z, Bister A, **Hoffmann MJ**, **Grunewald CM**, Hamacher A, Kassack M, Wiek C, Scheckenbach K, Hanenberg H

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 505976

[Current view on testicular tumors from a developmental biological perspective : Important biomarkers and molecular pathological investigations].

**Pathologie (Heidelb)** 2022; 43(6): 409-415; Impact Factor=1.0; Impact Factor 2024=0.7; Typ=English Abstract;Journal Article;Review;

**Stephan A**, **Kotthoff M**, Bremmer F, **Nettersheim D**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 498973

Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).

**Prostate** 2022; 82(8): 894-903; Impact Factor=2.8; Impact Factor 2024=2.5; Typ=Journal Article;

Holze S, Lemaire E, Mende M, Neuhaus P, Arthanareeswaran VK, Truss MC, Minh Do H, Dietel A, Teber D, Stützel KD, Hohenfellner M, **Rabenalt R**, **Albers P**, Stolzenburg JU

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 492519

[PIRADS-5 cases with negative targeted MRI/US fusion-guided biopsy].

**Rofo** 2022; 194(3): 241-244; Impact Factor=1.8; Impact Factor 2024=1.7; Typ=Journal Article;

Kasprowski L, Ullrich T, Boschheidgen M, Lopez-Cotarelo C, Kristiansen G, **Albers P**, Antoch G, Schimmöller L

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 504724

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression.

**Sci Data** 2022; 9(1): ; Impact Factor=9.8; Impact Factor 2024=6.9; Typ=Dataset;Journal Article;Research Support, Non-U.S. Gov't;

**Jaguva Vasudevan AA**, **Hoffmann MJ**, Poschmann G, Petzsch P, Wiek C, Stühler K, Köhrer K, **Schulz**

**WA, Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 503535

Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.

**Sci Rep** 2022; 12(1): ; Impact Factor=4.6; Impact Factor 2024=3.9; Typ=Journal Article;

Boschheidgen M, Schimmöller L, Doerfler S, **Al-Monajjed R**, Morawitz J, Ziayee F, **Mally D**, Quentin M, **Arsov C**, **Albers P**, Antoch G, Ullrich T

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 501773

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.

**Ther Adv Med Oncol** 2022; 14(): ; Impact Factor=4.9; Impact Factor 2024=4.2; Typ=Journal Article;

Dieckmann KP, Pokrivcak T, Geczi L, Niehaus D, Dralle-Filiz I, Matthies C, Dienes T, Zschäbitz S, Paffenholz P, Gschliesser T, Pichler R, Mego M, Bader P, Zengerling F, Heinzlbecker J, Krausewitz P, Krege S, Aurilio G, Aksoy C, Hentrich M, Seidel C, Törzsök P, Nestler T, Majewski M, **Hiestler A**, Buchler T, Vallet S, Studentova H, Schönburg S, Niedersüß-Beke D, Ring J, Trenti E, Heidenreich A, Wülfing C, Isbarn H, Pichlmeier U, Pichler M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 501120

Cognitive function in patients undergoing cystectomy for bladder cancer - results from a prospective observational study.

**Ther Adv Urol** 2022; 14(): ; Impact Factor=2.0; Impact Factor 2024=3.5; Typ=Journal Article;

**Grunewald CM**, **Feldmeier V**, Supprian T, **Albers P**, **Giessing M**, **Niegisch G**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 488703

[Metastatic urothelial carcinoma-guideline-based therapy and new options].

**Urologe A** 2022; 61(3): 265-272; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=English

Abstract;Journal Article;Review;

**Niegisch G**, von Amsberg G, **Rehlinghaus M**, **Grunewald CM**, Retz M

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 502061

[The IMPACT study-PSA-based prostate screening in Lynch syndrome].

**Urologe A** 2022; 61(5): 534-536; Impact Factor=n.a.; Impact Factor 2024=n.a.; Typ=Journal Article;

**Al-Monajjed R**, **Serón-Möller RF**, **Radtko JP**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 490235

Age-stratified outcomes after radical prostatectomy in a randomized setting (LAP-01): do younger patients have more to lose?

**World J Urol** 2022; 40(5): 1151-1158; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article;

Holze S, Bräunlich M, Mende M, Arthanareeswaran VK, Neuhaus P, Truss MC, Do HM, Dietel A, Franz T, Teber D, Heilsberg AK, Hohenfellner M, **Rabenalt R**, **Albers P**, Stolzenburg JU

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 486572

Can magnetic resonance imaging replace conventional computerized tomography for follow-up of

patients with testicular cancer? A systematic review.

**World J Urol** 2022; 40(12): 2843-2852; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Busch J, Schmidt S, **Albers P**, Heinzlbecker J, Kliesch S, Lackner J, Pfister D, Ruf C, Winter C, Zengerling F, Beyersdorff D  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 474541

Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer.

**World J Urol** 2022; 40(2): 327-334; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Brandt MP, Ruf C, Dieckmann KP, Syring I, Ruckes C, Nestler T, Schmelz HU, Dotzauer R, **Hiester A**, **Albers P**, **Nettersheim D**, Bolenz C, Loosen SH, Heidenreich A, Pfister D, Haferkamp A, Zengerling F, Paffenholz P, GESRU Academics Testis, Penile Cancer Group  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 496825

First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.

**World J Urol** 2022; 40(12): 2853-2861; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Pfister D, Oechsle K, Schmidt S, Busch J, Bokemeyer C, Heidenreich A, Heinzlbecker J, Ruf C, Winter C, Zengerling F, Kliesch S, **Albers P**, Oing C  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 503976

How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.

**World J Urol** 2022; 40(12): 2863-2878; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; **Winter C**, Zengerling F, Busch J, Heinzlbecker J, Pfister D, Ruf C, Lackner J, **Albers P**, Kliesch S, Schmidt S, Bokemeyer C  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 469665

Late relapsing germ cell tumors with elevated tumor markers.

**World J Urol** 2022; 40(2): 363-371; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; **Che Y**, **Lusch A**, **Winter C**, **Große Siemer R**, **Buddensieck C**, **Albers P**, **Hiester A**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 498970

Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility.

**World J Urol** 2022; 40(6): 1505-1512; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Fankhauser CD, Afferi L, Stroup SP, Rocco NR, Olson K, Bagrodia A, Baky F, Cazzaniga W, Mayer E, Nicol D, Islamoglu E, de Vergie S, Saoud R, Eggenner SE, Nazzani S, Nicolai N, Hugar L, Sexton WJ, Matei DV, De Cobelli O, Cheaib J, Pierorazio PM, Porter J, Hermanns T, Hamilton RJ, **Hiester A**, **Albers P**, Clarke N, Mattei A  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 472055

Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND).

**World J Urol** 2022; 40(2): 349-354; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; **Nini A**, Boschheidgen M, **Hiester A**, **Winter C**, Antoch G, Schimmöller L, **Albers P**  
Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 506002

Prognostic factors in patients with clinical stage I nonseminoma-beyond lymphovascular invasion: a systematic review.

**World J Urol** 2022; 40(12): 2879-2887; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Zengerling F, Beyersdorff D, Busch J, Heinzlbecker J, Pfister D, Ruf C, Winter C, **Albers P**, Kliesch S, Schmidt S

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 488712

Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.

**World J Urol** 2022; 40(2): 373-383; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Fichtner A, Bohnenberger H, Elakad O, Richter A, Lenz C, Oing C, Ströbel P, Kueffer S, **Nettersheim D**, Bremmer F

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 498400

Special Issue on Testis Cancer.

**World J Urol** 2022; 40(2): 305-306; Impact Factor=3.4; Impact Factor 2024=2.9;

Typ=Editorial;Comment;

**Nettersheim D, Albers P**

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 506984

Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review.

**World J Urol** 2022; 40(12): 2889-2900; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Ruf CG, Schmidt S, Kliesch S, Oing C, Pfister D, Busch J, Heinzlbecker J, Winter C, Zengerling F, **Albers P**, Oechsle K, Krege S, Lackner J, Dieckmann KP

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

ID: 473574

Therapy of clinical stage IIA and IIB seminoma: a systematic review.

**World J Urol** 2022; 40(12): 2829-2841; Impact Factor=3.4; Impact Factor 2024=2.9; Typ=Journal Article; Heinzlbecker J, Schmidt S, Lackner J, Busch J, Bokemeyer C, Classen J, Dieing A, Hakenberg O, Krege S, Papachristofilou A, Pfister D, Ruf C, Schmelz H, Schmidberger H, Souchon R, Winter C, Zengerling F, Kliesch S, **Albers P**, Oing C

Medline-ID vorhanden, Web of Science-ID (ISI-LOC) vorhanden

